

Anti-PAI-1 (human, plasminogen activator inhibitor type I)
Mouse monoclonal antibody

Subclass: IgG1

PRODUCT NO.

MON I-2

PRESENTATION

Preparation: Protein-G purified

Content: Available in 200 µL and 1 mL volumes, 1 mg/mL

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: In the dark at 4-8°C

ANTIGEN

Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer (1-5).

IMMUNOGEN

Native PAI-1

SPECIFICITY

MON I-2 is specific for human PAI-1. No cross-reactivity is observed with PAI-2 as tested by ELISA, immunoblotting and neutralization of inhibitory activity. No reactivity is observed with any other human plasma protein when tested by immunoblotting.

EPI TOPE SPECIFICITY

MON I-2 binds to an epitope consisting of amino acids 110-145

REACTIVITY

MON I-2 reacts with PAI-1 as tested by ELISA, immunoblotting, affinity purification and neutralization of inhibitory activity (6). Can be used as coating antibody for uPA:PAI-1 ELISA (8). For immunohistochemistry applications MON I-2 can be used on frozen sections.

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

NCI-Ag 4/1

IMMUNIZATION

Female BALB/c mice immunized by intradermal injection

APPLICATION

Method	Usability	Dilution guideline	References
ELISA	Yes		7,8
Immunoblotting	Yes		
Immunohistochemistry	Yes		

REFERENCES

- Andreasen PA (2007) PAI-1 - a potential therapeutic target in cancer. *Current Drug Target* 9:1030-1041
- Loskutoff DJ, Curriden SA, Hu G, Deng G (1999) Regulation of adhesion by PAI-1. *APMIS* 107:54-61.
- Andreasen PA, Kjølner L, Christensen (1997) The urokinase plasminogen activator system in cancer metastasis. A review. *Int J Cancer* 2:1-22.
- Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase -type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). *Cancer Res* 62:4617-22.
- Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. *Cancer Res* 53:2513-2521
- Nielsen LS, Andreasen PA, Grøndahl-Hansen J, Huang J Y, Kristensen P, Danø K (1986) Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells Inhibitor neutralization and one step affinity purification. *Thrombos Haemostas* 55:206 212.
- Lund LR, Georg B, Nielsen LS, Mayer M, Danø K, Andreasen PA (1988) Plasminogen activator inhibitor type 1: Cell specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme linked immunosorbent assay. *Mol Cell Endocrinol* 60:43 53.
- Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. *J Imm Meth* 203:55-65.

CONDITIONS

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.